The company's thrombosis drug is very important, as it acts as a blood thinner without causing the patient to bleed out, TheStreet's Jim Cramer, portfolio manager of the Action Alerts PLUS portfolio, said on CNBC's "Stop Trading" segment.
This is a very big drug and a very big milestone, but investors should wait to hear what Dr. Stanley Crooke has to say when the company's CEO meets with Cramer on tonight's "Mad Money" TV show.
Turning to Tesla Motors (TSLA), Cramer says the stock has become a "battleground" between bulls and bears. Investors seem to expect weak earnings results from the automaker when it reports on Wednesday after the close.
With these types of companies that have a lot of potential but also a very high valuation, investors either buy into the story or they don't. Right now, there don't seem to be a lot of people buying in, Cramer said.